GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2018-2026

The Global Alzheimer’s disease diagnostic and therapeutic market is anticipated to grow at a CAGR of 7.50% between 2018 and 2026. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that mostly affects people above the age of 65. The Alzheimer’s disease diagnostic and therapeutic market is primarily driven by the following factors:

• Growing geriatric population
• The rise in the pervasiveness of Alzheimer’s disease
• Increasing healthcare expenditure
• Government investment in research and development

To learn more about this report, request a free sample copy

The important driver increasing growth in the global Alzheimer’s disease diagnostic and therapeutic market is the rise in the pervasiveness of Alzheimer’s disease. The high prevalence of Alzheimer’s disease globally acts as a key driver for the growth of the global Alzheimer’s disease therapeutics and diagnostics market and emphasizes the need to develop an effective Alzheimer’s disease treatment. For instance, according to the Alzheimer’s Association in 2016, a projected 5.4 million of the American residents across every age group suffer from Alzheimer’s.

The Therapeutics and diagnostics of Alzheimer’s disease diagnostic and therapeutic market are used extensively for the treatment of Alzheimer’s diseases. The Alzheimer’s disease therapeutics and diagnostics market is segmented into therapeutics and diagnostics. Global Alzheimer’s disease therapeutics and diagnostics by marketed drugs market comprise of the market for drugs such as NMDA receptor antagonists, Cholinesterase inhibitors and other drugs that are used for therapeutic treatment of Alzheimer’s. The general course of the AD is categorized into seven stages according to disease severity; however, because it is difficult to clearly distinguish each stage, in drug development a three-stage categorization is preferred: mild, moderate and severe AD. Treatment, or more accurately the prevention of AD, during the prodromal stage of the disease, is an expected trend for the global market for AD therapeutics in the mid-term future. A branded medicine is the original product that has been developed by a pharmaceutical company. Generic drugs are replicas of brand-name medicines that have precisely the effects and side effects, intended use, same dosage, route of administration, safety, risks, and forte as the novel drug. Alzheimer’s disease therapeutics and diagnostic market by diagnostics include the market for diagnostics biomarker.

Stringent government regulations and the high cost of therapies used for the treatment of Alzheimer’s Disease are the major factors hindering the Alzheimer’s disease diagnostic and therapeutic market. As per the Alzheimer’s Drug Discovery Foundation, pharmacologic treatments for Alzheimer are first tested in clinical trials registered with ‘Clinical Trials Government’, a national institute of health registry of publicly and privately funded clinical studies. The high cost of therapies used for the treatment of Alzheimer’s disease is one of the major factors restraining the growth of global Alzheimer’s disease therapeutics and diagnostics market.

The Global Alzheimer’s disease diagnostic and therapeutic market segment includes therapeutics and diagnostics.

Therapeutics and diagnostics are further segmented into:

• Therapeutics
  • Therapeutics by drugs
    • Marketed drugs
    • Pipeline drugs
  • Therapeutics by disease stage
    • Late stage: severe ad
    • Early/middle stage: mild to moderate ad
    • Prodromal stage
  • Therapeutics by generic and branded
    • Branded
    • Generic
  • Diagnostics
    • Lumbar puncture test
    • Positron emission tomography
    • Electroencephalography
    • Magnetic resonance imaging
    • Computed tomography
    • Other diagnostics

This report covers the present market conditions and the growth prospects of the global Alzheimer’s disease diagnostic and therapeutic market for 2018-2026 and considered the revenue generated through the sales of Alzheimer’s disease diagnostic and therapeutics to calculate the market size by considering 2017 as the base year.

Geographically, the global Alzheimer’s disease diagnostic and therapeutic market has been segmented on the basis of four major regions, which include:

• Alzheimer’s Disease Diagnostics and Therapeutics North America Market: The United States & Canada
• Alzheimer’s Disease Diagnostics and Therapeutics Asia-Pacific Market: China, India, Japan, Australia & Rest of APAC
• Alzheimer’s Disease Diagnostics and Therapeutics Europe Market: The UK, France, Germany, Spain & Rest of Europe
• Rest of World: Latin America & Middle East and Africa

The Alzheimer’s disease diagnostic and therapeutic market in North America is expected to hold the largest share by 2026 owing to the rising prevalence of Alzheimer’s disease along with investments made by the government institutions in research & development activities for Alzheimer’s. Due to the prospect of new therapies gaining market approval and the anticipated growth in sales of the extended-release formulation of Namenda and  Namenda XR, the market for AD therapeutics in North America is anticipated to increase. On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the Alzheimer’s disease diagnostic and therapeutic market. Aggressive marketing and sales of AD therapeutics in India and China, and the introduction of the three globally common AD therapeutics, Exelon (rivastigmine), Reminyl (galantamine) and Memary (memantine) in Japan is likely to fuel the growth in the market for AD therapeutics in Asia-Pacific through the projected years.

The major market players in the global Alzheimer’s disease diagnostic and therapeutic market are:

• ABBVIE INC.
• AXON NEUROSCIENCE SE
• BIOGEN INC.
• HOFFMANN-LA ROCHE AG
• MERCK AND CO.

Company Profiles covers analysis of important players.

AbbVie is a global, research-based biopharmaceutical company that was spun off from Abbott Laboratories in 2011 to intensify research-based pharmaceutical development. AbbVie develops and markets advanced therapies that are used for treating chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease (CKD) and cystic fibrosis, among other health conditions. Merck and Co. is the world’s seventh largest pharmaceutical company by market capitalization and revenue. Its headquarters is located in New Jersey, the U.S. The company is currently carrying out Phase II and III clinical studies on the treatment of Alzheimer’s disease.

Key Findings of the Global Alzheimer’s disease diagnostic and therapeutic market:

• Computed tomography is majorly used in the diagnostics of Alzheimer’s disease
• Therapeutics market constitutes the largest market share
• North America is the market leader in Alzheimer’s disease diagnostic and therapeutic market